Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

Efforts to further elucidate structure-activity relationships (SAR) within our previously disclosed series of beta-quaternary amino acid linked l-cis-4,5-methanoprolinenitrile dipeptidyl peptidase IV (DPP-IV) inhibitors led to the investigation of vinyl substitution at the beta-position of alpha-cycloalkyl-substituted glycines. Despite poor systemic exposure, vinyl-substituted compounds showed extended duration of action in acute rat ex vivo plasma DPP-IV inhibition models. Oxygenated putative metabolites were prepared and were shown to exhibit the potency and extended duration of action of their precursors in efficacy models measuring glucose clearance in Zucker(fa/fa) rats. Extension of this approach to adamantylglycine-derived inhibitors led to the discovery of highly potent inhibitors, including hydroxyadamantyl compound BMS-477118 (saxagliptin), a highly efficacious, stable, and long-acting DPP-IV inhibitor, which is currently undergoing clinical trials for treatment of type 2 diabetes.

[1]  L. B. Knudsen.  Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. , 2004, Journal of medicinal chemistry.

[2]  Jay S Skyler,et al.  Diabetes mellitus: pathogenesis and treatment strategies. , 2004, Journal of medicinal chemistry.

[3]  R. Parker,et al.  Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of alpha-aminoacyl-l-cis-4,5-methanoprolinenitrile-based inhibitors. , 2004, Journal of medicinal chemistry.

[4]  Silja Weber,et al.  Aminomethylpyrimidines as novel DPP-IV inhibitors: a 10(5)-fold activity increase by optimization of aromatic substituents. , 2004, Bioorganic & medicinal chemistry letters.

[5]  E. Gulve,et al.  Chemistry and biochemistry of type 2 diabetes. , 2004, Chemical reviews.

[6]  Walter Huber,et al.  Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV. , 2003, Structure.

[7]  J. Holst,et al.  Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects , 2003, Regulatory Peptides.

[8]  D. Moller,et al.  Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. Van der Veken,et al.  Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes , 2003 .

[10]  P. Wiedeman,et al.  Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes. , 2003, Current opinion in investigational drugs.

[11]  Koji Inaka,et al.  The structure and function of human dipeptidyl peptidase IV, possessing a unique eight-bladed β-propeller fold , 2003 .

[12]  C. Abbott,et al.  Structural requirements for catalysis, expression, and dimerization in the CD26/DPIV gene family. , 2003, Biochemistry.

[13]  Sven Branner,et al.  Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog , 2003, Nature Structural Biology.

[14]  Michael B Wheeler,et al.  The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. , 2002, Diabetes.

[15]  Bo Ahrén,et al.  Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. , 2002, Diabetes care.

[16]  J. Holst,et al.  Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. , 2000, European journal of pharmacology.

[17]  T. Hughes,et al.  NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. , 1999, Biochemistry.

[18]  J. Holst,et al.  The Inhibitory Effect of Glucagon-Like Peptide-1 (7-36)amide on Antral Motility is Antagonized by Its N-Terminally Truncated Primary Metabolite GLP-1 (9-36)amide , 1998, Peptides.

[19]  U. Kazmaier.  Application of the Ester Enolate Claisen Rearrangement in the Synthesis of Amino Acids Containing Quaternary Carbon Centers. , 1996, The Journal of organic chemistry.

[20]  Paul D. Jenkins,et al.  2-cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV , 1996 .

[21]  R. Pederson,et al.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.

[22]  M. Fujita,et al.  An Efficient and Practical Synthesis of L-α-Amino Acids Using (R)-Phenylglycinol as a Chiral Auxiliary , 1992 .

[23]  J. Friedman,et al.  Rat obesity gene fatty (fa) maps to chromosome 5: evidence for homology with the mouse gene diabetes (db). , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Y. Misumi,et al.  Primary structure of rat liver dipeptidyl peptidase IV deduced from its cDNA and identification of the NH2-terminal signal sequence as the membrane-anchoring domain. , 1989, The Journal of biological chemistry.

[25]  C. Walsh,et al.  The behavior and significance of slow-binding enzyme inhibitors. , 2006, Advances in enzymology and related areas of molecular biology.

[26]  I. Harruna,et al.  Novel Synthesis of 3-Fluoro-1-Aminoadamantane and Some of its Derivatives , 1988 .

[27]  N. Benoiton,et al.  Studies on racemization during couplings using a series of model tripeptides involving activated residues with unfunctionalized side chains. , 2009, International journal of peptide and protein research.

[28]  Giovanni Casini,et al.  A convenient synthesis of nitriles from primary amides under mild conditions , 1977 .